What are the appropriate indications, dosing schedule, contraindications, dietary restrictions, and monitoring recommendations for phenelzine (monoamine oxidase inhibitor) in patients with major depressive disorder?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 12, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Phenelzine for Major Depressive Disorder

Phenelzine is a monoamine oxidase inhibitor (MAOI) reserved for treatment-resistant depression, particularly in patients with atypical features who have failed to respond to second-generation antidepressants. It should not be used as a first-line agent 1.

Indications

Phenelzine is FDA-approved for depressed patients clinically characterized as "atypical," "nonendogenous," or "neurotic"—often presenting with mixed anxiety and depression, phobic features, or hypochondriacal symptoms 1. It should rarely be the first antidepressant used; rather, it is more suitable for patients who have failed to respond to drugs more commonly used for these conditions 1.

Current guidelines recommend second-generation antidepressants (SSRIs, SNRIs) as first-line treatment based on adverse effect profiles, cost, and patient preferences 2. MAOIs like phenelzine are typically considered third- to fifth-line treatments due to dietary restrictions and drug interaction concerns 3.

Dosing Schedule

Initial dose: Start with 15 mg three times daily (45 mg/day total) 1.

Titration: Increase fairly rapidly to at least 60 mg/day, consistent with patient tolerance. May increase up to 90 mg/day to obtain sufficient MAO inhibition 1.

Response timeline: Many patients do not show clinical response until treatment at 60 mg has been continued for at least 4 weeks 1.

Maintenance dose: After maximum benefit is achieved, reduce slowly over several weeks. Maintenance may be as low as 15 mg daily or every other day, continued for as long as required 1. Evidence supports maintaining the full therapeutic dose for at least 6 months to prevent relapse 4. For patients with recurrent depression (≥2 episodes), longer maintenance treatment is beneficial 5.

Absolute Contraindications

Phenelzine is absolutely contraindicated with:

  • Any other MAOI (including isocarboxazid, moclobemide, isoniazid, linezolid) 6
  • SSRIs, SNRIs, or other serotonergic antidepressants (risk of serotonin syndrome) 6, 1
  • Sympathomimetic agents (nasal decongestants, stimulants, "pep pills") 1
  • Dextromethorphan 1
  • Meperidine, tramadol, methadone, fentanyl 6
  • Uncontrolled hypertension 7

Dietary Restrictions

Patients must strictly avoid tyramine-containing foods to prevent hypertensive crisis 1, 8:

High-risk foods to avoid completely:

  • Aged cheeses (cottage cheese and cream cheese are allowed)
  • Pickled herring
  • Liver
  • Dry/aged sausages (Genoa salami, hard salami, pepperoni, Lebanon bologna)
  • Broad bean pods (fava beans)
  • Sauerkraut
  • Beer and wine (including alcohol-free/reduced-alcohol products)
  • Yeast extract (including large quantities of brewer's yeast)
  • Meat extract
  • Any spoiled or improperly stored protein-rich foods

Moderate intake:

  • Limit excessive amounts of chocolate and caffeine 1

Continue dietary restrictions for 2 weeks after discontinuing phenelzine 1, as MAO inhibition persists during this period.

Monitoring Recommendations

Initial monitoring (first 1-2 months):

  • Blood pressure monitoring: Check frequently to detect any pressor response; measure at every visit 1. Hypertensive crisis is the most serious reaction.
  • Suicidality assessment: Monitor closely for increases in suicidal thoughts and behaviors, particularly in the first 1-2 months when risk is highest 1. Begin monitoring within 1-2 weeks of initiation 2.
  • Behavioral changes: Watch for agitation, irritability, unusual behavior changes, anxiety, panic attacks, insomnia, hostility, aggressiveness, impulsivity, akathisia, hypomania, or mania 1.

Ongoing monitoring:

  • Assess therapeutic response and adverse effects regularly 2
  • Modify treatment if inadequate response after 6-8 weeks 2
  • Screen for bipolar disorder before initiating treatment, as antidepressants may precipitate manic episodes 1

Critical Safety Warnings

Hypertensive crisis symptoms (medical emergency):

  • Occipital headache radiating frontally
  • Palpitations, chest pain
  • Neck stiffness or soreness
  • Nausea, vomiting
  • Sweating (with fever or cold/clammy skin)
  • Dilated pupils, photophobia
  • Tachycardia or bradycardia

If hypertensive crisis occurs: Discontinue phenelzine immediately. Administer phentolamine 5 mg IV slowly to avoid excessive hypotension 1. Intracranial bleeding has been reported with severe hypertension 1.

Serotonin syndrome risk: Can occur within 24-48 hours when combining with other serotonergic agents. Symptoms include mental status changes (confusion, agitation), neuromuscular hyperactivity (tremors, clonus, hyperreflexia, rigidity), and autonomic hyperactivity (hypertension, tachycardia, diaphoresis). Advanced symptoms include fever, seizures, arrhythmias, unconsciousness, and can be fatal 6. Requires immediate hospitalization, discontinuation of all serotonergic agents, and supportive care with cardiac monitoring 6.

Common Pitfalls to Avoid

  • Do not use phenelzine as first-line treatment—reserve for treatment-resistant cases 1
  • Do not combine with any serotonergic medication—even "mild" combinations can cause fatal serotonin syndrome 6
  • Do not allow rapid washout periods when switching MAOIs—though recent case reports suggest shorter washouts may be safe 9, standard practice requires 1-2 weeks
  • Do not prescribe large quantities—write prescriptions for smallest quantity consistent with good management to reduce overdose risk 1
  • Do not assume all cheeses are prohibited—modern food production has reduced tyramine in many cheeses, though aged varieties remain high-risk 10

References

Research

Use of phenelzine in continuation therapy.

Neuropsychobiology, 1984

Guideline

clinical practice guideline for the assessment and treatment of children and adolescents with anxiety disorders.

Journal of the American Academy of Child and Adolescent Psychiatry, 2020

Guideline

american association of clinical endocrinologists and american college of endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologist, 2016

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.